{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:09:19Z","timestamp":1789711759382,"version":"4.0.1"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Aniridia is a rare congenital vision-loss disorder primarily caused by variants in the paired box 6 (\n                      <jats:italic>PAX6<\/jats:italic>\n                      ) gene. Current treatments do not maintain vision long term, nor address the underlying disease mechanism. CRISPR-mediated genome editing holds great promise for treating genetic diseases but requires demonstration of efficacy on human DNA to support translational relevance. The aim of this work was to generate and test a minimally humanized mouse model of aniridia, carrying a FLAG-tagged\n                      <jats:italic>Pax6<\/jats:italic>\n                      and the most common recurring pathogenic aniridia-patient variant, introduced for the first time in mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ocular assessments (gross examination, slit lamp imaging, and fluorescent and confocal microscopy) were performed in mice homozygous for humanization and heterozygous for the variant, paralleling patients. Mice were examined immediately post-wean and at adulthood, with the former chosen as a likely time for treatment initiation. As an exploratory proof-of-principle, a lipid nanoparticle-delivered adenine base editor (ABE8e) was tested to demonstrate the utility of the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ocular assessments revealed the expected phenotypes for an aniridia mouse model, supporting successful generation and phenotypic validation of the humanized mouse. The ABE8e treatment resulted in a modest correction (4.8% \u00b1 0.4% SEM) of the pathogenic variant in clinically relevant ex vivo cortical neurons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although designed for the development of genome editing therapies, this humanized mouse is also applicable to other therapies requiring interaction with human DNA or RNA. It also enables evaluation of nonsense-suppression drugs since the readthrough proteins retain the FLAG tag. More broadly, this methodology is applicable to other pathogenic variants for aniridia, CRISPRa approaches, and other genetic diseases for which CRISPR-based therapy holds promise.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgeed.2026.1910209","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:39:25Z","timestamp":1789709965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel minimally humanized mouse model of aniridia for preclinical evaluation of CRISPR gene editing strategies"],"prefix":"10.3389","volume":"8","author":[{"given":"Seyedeh Zeinab","family":"Mirjalili Mohanna","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Korecki","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Kazemian","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess C.","family":"Lengyell","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany A.","family":"Adair","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"The Djavad Mowafaghian Centre for Brain Health, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Division of Neurology, Department of Medicine, University of British Columbia Hospital","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, the University of British Columbia","place":["Vancouver, BC, Canada"]},{"name":"Centre for Molecular Medicine and Therapeutics at BC Children\u2019s Hospital, the University of British Columbia","place":["Vancouver, BC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"26436","DOI":"10.1038\/s41598-024-76654-w","article-title":"Effects of miR-204-5p modulation on PAX6 regulation and corneal inflammation","volume":"14","author":"Abbasi","year":"2024","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s40123-023-00729-6","article-title":"ABE8e corrects Pax6-Aniridic variant in humanized mouse ESCs and via LNPs in Ex Vivo cortical neurons","volume":"12","author":"Adair","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1167\/iovs.07-1630","article-title":"Effects of elevated Pax6 expression and genetic background on mouse eye development","volume":"50","author":"Chanas","year":"2009","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.addr.2020.10.014","article-title":"Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-Mediated genome editing","volume":"168","author":"Chen","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"109723","DOI":"10.1016\/j.exer.2023.109723","article-title":"Characterization of neural damage and neuroinflammation in Pax6 small-eye mice","volume":"238","author":"Cole","year":"2024","journal-title":"Exp. Eye Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0012-1606(02)00095-7","article-title":"The roles of Pax6 in the cornea, retina, and olfactory epithelium of the developing mouse embryo","volume":"255","author":"Collinson","year":"2003","journal-title":"Dev. Biol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"118506","DOI":"10.1016\/j.biopha.2025.118506","article-title":"Targeting insulin receptor substrate-1 delays disease progression in a murine model of aniridia-associated keratopathy","volume":"191","author":"Dashti","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrg3116","article-title":"Genomically humanized mice: technologies and promises","volume":"13","author":"Devoy","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-026-00605-5","article-title":"First pilot study of intravenous rAAV-PAX6 gene therapy increases retinal-ganglion-cell-layer thickness and Notch1 transcription in a mouse model of aniridia","author":"Djaksigulova","year":"2026","journal-title":"Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/humu.21438","article-title":"LOVD v.2.0: the next generation in gene variant databases","volume":"32","author":"Fokkema","year":"2011","journal-title":"Hum. Mutat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1089\/hum.2024.170","article-title":"Minimally humanized Ezh2 Exon-18 mouse cell lines validate preclinical CRISPR\/Cas9 approach to treat weaver syndrome","volume":"36","author":"Gibson","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1172\/JCI70462","article-title":"Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects","volume":"124","author":"Gregory-Evans","year":"2013","journal-title":"J. Clin. Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1042588","DOI":"10.3389\/fmed.2022.1042588","article-title":"Novel clinical presentation and PAX6 mutation in families with congenital aniridia","volume":"9","author":"Guo","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40123-025-01122-1","article-title":"Comprehensive analysis of congenital aniridia and differential diagnoses: genetic insights and clinical manifestations","volume":"14","author":"Hall","year":"2025","journal-title":"Ophthalmol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-cas genome editing in human primary cells","volume":"33","author":"Hendel","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"16051","DOI":"10.1038\/mtm.2016.51","article-title":"PAX6 MiniPromoters drive restricted expression from rAAV in the adult mouse retina","volume":"3","author":"Hickmott","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41434-018-0043-6","article-title":"Epistasis between Pax6(Sey) and genetic background reinforces the value of defined hybrid mouse models for therapeutic trials","volume":"25","author":"Hickmott","year":"2018","journal-title":"Gene Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/354522a0","article-title":"Mouse small eye results from mutations in a paired-like homeobox-containing gene","volume":"354","author":"Hill","year":"1991","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ejhg.2012.100","article-title":"Aniridia","volume":"20","author":"Hingorani","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"12555","DOI":"10.1016\/j.ymthe.2018.02.028","article-title":"Nuclease-free adeno-associated virus-mediated Il2rg gene editing in X-SCID mice","volume":"26","author":"Hiramoto","year":"2018","journal-title":"Mol. Ther."},{"key":"B24","first-page":"95","article-title":"Small eyes (sey): a homozygous lethal mutation on chromosome 2 which affects the differentiation of both lens and nasal placodes in the mouse","volume":"97","author":"Hogan","year":"1986","journal-title":"J. Embryol. Exp. Morphol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabg2661","DOI":"10.1126\/sciadv.abg2661","article-title":"High-purity production and precise editing of DNA base editing ribonucleoproteins","volume":"7","author":"Jang","year":"2021","journal-title":"Sci. Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e183965","DOI":"10.1172\/jci.insight.183965","article-title":"A human-like model of aniridia-associated keratopathy for mechanistic and therapeutic studies","volume":"10","author":"Javidjam","year":"2024","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/iovs.67.1.37","article-title":"Transcriptomic analysis in a model of aniridia-associated keratopathy for target discovery and evaluation of duloxetine therapy","volume":"67","author":"Javidjam","year":"2026","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ng0892-328","article-title":"The human PAX6 gene is mutated in two patients with aniridia","volume":"1","author":"Jordan","year":"1992","journal-title":"Nat. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"201786","DOI":"10.1016\/j.omta.2026.201786","article-title":"First pilot study of intrastromal rAAV-PAX6 gene therapy suggests improved corneal thickness and transcription correction in aniridic mouse","volume":"34","author":"Kaad","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-Guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e148406","DOI":"10.1172\/jci.insight.148406","article-title":"Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia","volume":"6","author":"Kit","year":"2021","journal-title":"JCI Insight"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1093\/hmg\/10.19.2049","article-title":"Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6","volume":"10","author":"Kleinjan","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/crispr.2018.0014","article-title":"EditR: a method to quantify base editing from sanger sequencing","volume":"1","author":"Kluesner","year":"2018","journal-title":"CRISPR J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e202304","DOI":"10.21542\/gcsp.2023.4","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"B37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ophtha.2019.09.034","article-title":"PAX6 mutational status determines aniridia-associated keratopathy phenotype","volume":"127","author":"Lagali","year":"2019","journal-title":"Ophthalmology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jcyt.2022.11.013","article-title":"CRISPR-Cas9 base editors and their current role in human therapeutics","volume":"25","author":"Lahr","year":"2023","journal-title":"Cytotherapy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: public archive of interpretations of clinically relevant variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B40","first-page":"105","volume-title":"The Genetics of Congenital Aniridia - A Guide for the Ophthalmologist. Surv Ophthalmol","author":"Landsend","year":"2017"},{"key":"B41","first-page":"1031","volume-title":"Congenital Aniridia - A Comprehensive Review of Clinical Features and Therapeutic Approach. Surv. Ophthalmol","author":"Landsend","year":"2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/d41586-025-03566-8","article-title":"Personalized gene editing helped one baby: can it be rolled out widely?","volume":"647","author":"Ledford","year":"2025","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient Mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J. Biotechnol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/genes10121050","article-title":"The spectrum of PAX6 mutations and genotype-phenotype correlations in the eye","volume":"10","author":"Lima Cunha","year":"2019","journal-title":"Genes (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1515\/mr-2022-0044","article-title":"Precise genome editing with base editors","volume":"3","author":"Liu","year":"2023","journal-title":"Med. Rev. (2021)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.stem.2014.10.004","article-title":"Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR\/Cas9","volume":"15","author":"Mandal","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1242\/dev.02764","article-title":"Controlled overexpression of Pax6 in vivo negatively autoregulates the Pax6 locus, causing cell-autonomous defects of late cortical progenitor proliferation with little effect on cortical arealization","volume":"134","author":"Manuel","year":"2007","journal-title":"Development"},{"key":"B49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.neuron.2012.10.002","article-title":"The neuronal organization of the retina","volume":"76","author":"Masland","year":"2012","journal-title":"Neuron"},{"key":"B50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.omtm.2020.03.002","article-title":"Germline CRISPR\/Cas9-Mediated gene editing prevents vision loss in a novel mouse model of aniridia","volume":"17","author":"Mirjalili Mohanna","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B51","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","article-title":"LNP-Mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea","volume":"350","author":"Mirjalili Mohanna","year":"2022","journal-title":"J. Control Release"},{"key":"B52","article-title":"PAX6-Related aniridia","volume-title":"Genereviews","author":"Moosajee","year":"1993"},{"key":"B53","doi-asserted-by":"publisher","first-page":"104986","DOI":"10.1016\/j.neures.2025.104986","article-title":"Experimental modeling for tauopathies: an isogenic panel of humanized MAPT knock-in mice","volume":"221","author":"Morito","year":"2025","journal-title":"Neurosci. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ajo.2026.07.020","article-title":"Shaping the future of limbal stem cell therapy: advances in substrates, techniques, and science for cultivated autologous and allogeneic limbal-epithelial transplantation","volume":"291","author":"Naderi","year":"2026","journal-title":"Am. J. Ophthalmol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/bjo.83.6.723","article-title":"PAX6 expression in the developing human eye","volume":"83","author":"Nishina","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41467-024-55137-6","article-title":"Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering","volume":"16","author":"Padilla","year":"2025","journal-title":"Nat. Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1167\/iovs.61.5.14","article-title":"PAX6 genotypic and retinal phenotypic characterization in congenital aniridia","volume":"61","author":"Pedersen","year":"2020","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-Associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"149938","DOI":"10.1016\/j.gene.2025.149938","article-title":"CRISPR 2.0: expanding the genome engineering toolbox for epigenetics, RNA editing, and molecular diagnostics","volume":"979","author":"Pradhan","year":"2025","journal-title":"Gene"},{"key":"B61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/hum.2020.231","article-title":"Genome-editing strategies for treating human retinal degenerations","volume":"32","author":"Quinn","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1167\/iovs.02-0576","article-title":"Corneal abnormalities in Pax6+\/- small eye mice mimic human aniridia-related keratopathy","volume":"44","author":"Ramaesh","year":"2003","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1101\/pdb.top069799","article-title":"Genetically engineered knock-in and conditional knock-in mouse models of cancer","volume":"2014","author":"Rappaport","year":"2014","journal-title":"Cold Spring Harb. Protoc."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2016.73","article-title":"Clinical utility gene card for: aniridia","volume":"24","author":"Richardson","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"B65","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41596-021-00666-3","article-title":"dCas9-VPR-mediated transcriptional activation of functionally equivalent genes for gene therapy","volume":"17","author":"Riedmayr","year":"2022","journal-title":"Nat. Protoc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice","volume":"13","author":"Riviere","year":"2006","journal-title":"Gene Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/aos.17587","article-title":"Congenital aniridia: european COST action ANIRIDIA-NET guidelines for diagnosis, management and care","volume":"104","author":"Romano","year":"2025","journal-title":"Acta Ophthalmol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0092-8674(00)80078-1","article-title":"Influence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities","volume":"86","author":"Schedl","year":"1996","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.preteyeres.2012.04.002","article-title":"Pax6: a multi-level regulator of ocular development","volume":"31","author":"Shaham","year":"2012","journal-title":"Prog. Retin Eye Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1021\/acs.molpharmaceut.3c00547","article-title":"Differences and similarities of the intravenously administered lipid nanoparticles in three clinical trials: potential linkage between lipid nanoparticles and extracellular vesicles","volume":"20","author":"Suzuki","year":"2023","journal-title":"Mol. Pharm."},{"key":"B73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/crispr.2020.0025","article-title":"Translating CRISPR-cas therapeutics: approaches and challenges","volume":"3","author":"Tay","year":"2020","journal-title":"CRISPR J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0888-7543(92)90239-o","article-title":"Small eye (sey): cloning and characterization of the murine homolog of the human aniridia gene","volume":"13","author":"Ton","year":"1992","journal-title":"Genomics"},{"key":"B75","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/cercor\/13.6.612","article-title":"Pax6 regulates cell adhesion during cortical development","volume":"13","author":"Tyas","year":"2003","journal-title":"Cereb. Cortex"},{"key":"B76","doi-asserted-by":"publisher","first-page":"D626","DOI":"10.1093\/nar\/gkw1134","article-title":"The UCSC genome browser database: 2017 update","volume":"45","author":"Tyner","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B77","first-page":"940","article-title":"Future Directions in Managing aniridia-associated Keratopathy","volume-title":"Surv. Ophthalmol","author":"van Velthoven","year":"2023"},{"key":"B78","doi-asserted-by":"publisher","first-page":"114207","DOI":"10.1016\/j.ejpb.2024.114207","article-title":"Comparative analysis of lipid nanoparticle-mediated delivery of CRISPR-Cas9 RNP versus mRNA\/sgRNA for gene editing in vitro and in vivo","volume":"196","author":"Walther","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B79","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omtn.2017.05.002","article-title":"Efficacy of postnatal in vivo nonsense suppression therapy in a Pax6 mouse model of aniridia","volume":"7","author":"Wang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B80","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygeno.2008.09.014","article-title":"Next generation tools for high-throughput promoter and expression analysis employing single-copy knock-ins at the Hprt1 locus","volume":"93","author":"Yang","year":"2009","journal-title":"Genomics"},{"key":"B82","doi-asserted-by":"publisher","first-page":"106112","DOI":"10.1016\/j.neubiorev.2025.106112","article-title":"Humanized rodent models of neurodegenerative diseases and other brain disorders","volume":"172","author":"Zhang","year":"2025","journal-title":"Neurosci. Biobehav Rev."}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1910209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:39:27Z","timestamp":1789709967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2026.1910209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":82,"alternative-id":["10.3389\/fgeed.2026.1910209"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2026.1910209","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1910209"}}